Scarica l'app Stockscreener
59.12
0.77%
-0.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors - GlobeNewswire Inc.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now? - Zacks Investment Research
2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One) - The Motley Fool
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward? - Zacks Investment Research
Can Redwire's Microgravity Pharma Work Create New Revenue Streams? - Zacks Investment Research
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Zacks Investment Research
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol-Myers Squibb: Patent Cliff Is Still A Problem (NYSE:BMY) - Seeking Alpha
Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA - Zacks Investment Research
Bristol-Myers Squibb Co (BMY) Shares Fall 3.8% -- GF Value Says Still Overvalued - GuruFocus
Bristol-Myers Squibb Co: Prelim Total Acquire - Moomoo
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.56% on Oct 5: What Investors Need To Know - TradingKey
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol Myers Squibb (BMY) withholds 2,332 shares for taxes as Cari Gallman's stock award vests. - Stock Titan
Bristol Myers Squibb Co. Research & Ratings | BMY - Barron's
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt - Investing.com
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt - Yahoo Finance
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now? - Zacks Investment Research
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement - Yahoo Finance
Bristol Myers Squibb Co. Research & Ratings | BMY - Barron's
Bristol-Myers Squibb (NYSE:BMY) Dividend Quality: High Yield, Sustainability Concerns - ChartMill
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? - The Motley Fool
CX Institutional Sells 208,135 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) director Arduini now holds 74,077 deferred stock units. - Stock Titan
After acquiring 620.994 deferred stock units, Rice holds 42,084.867 at Bristol Myers Squibb (BMY). - Stock Titan
Director Michael R. McMullen acquires 560.897 deferred stock units at Bristol Myers Squibb (BMY). - Stock Titan
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs - BioSpace
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio? - TradingView
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale - The Globe and Mail
Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights - GlobeNewswire Inc.
Bristol Myers Squibb (BMY) Boosts Champions in Care Initiative w - gurufocus.com
Healthcare professionals can nominate nonprofits for Bristol Myers Squibb's $1 million grants - Stock Titan
Children with this heart condition have one FDA-approved option: Bristol Myers Squibb's CAMZYOS. - Stock Titan
FDA Approves Bristol Myers Squibb's Camzyos for Pediatric Obstru - gurufocus.com
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Zacks Investment Research
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - BioSpace
Novo Nordisk Gives Uninspiring Outlook - The Motley Fool
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - Zacks Investment Research
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation - fool.com
0.40%
1.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):